AU2004281154A1 - 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer - Google Patents

2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Download PDF

Info

Publication number
AU2004281154A1
AU2004281154A1 AU2004281154A AU2004281154A AU2004281154A1 AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1 AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1
Authority
AU
Australia
Prior art keywords
compound
substituted
heteroaryl
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004281154A
Other languages
English (en)
Inventor
Savithri Ramurthy
Paul A. Renhowe
Sharadha Subramanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2004281154A1 publication Critical patent/AU2004281154A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004281154A 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Abandoned AU2004281154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51185103P 2003-10-16 2003-10-16
US60/511,851 2003-10-16
PCT/US2004/034185 WO2005037285A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2004281154A1 true AU2004281154A1 (en) 2005-04-28

Family

ID=34465285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004281154A Abandoned AU2004281154A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer

Country Status (10)

Country Link
US (3) US20050084835A1 (https=)
EP (1) EP1680122A1 (https=)
JP (1) JP2007509059A (https=)
KR (1) KR20070029110A (https=)
CN (1) CN1882345A (https=)
AU (1) AU2004281154A1 (https=)
CA (1) CA2542329A1 (https=)
IL (1) IL174470A0 (https=)
MX (1) MXPA06003607A (https=)
WO (1) WO2005037285A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20060292537A1 (en) * 2005-06-27 2006-12-28 Arcturus Media, Inc. System and method for conducting multimedia karaoke sessions
CN101365682A (zh) 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
ES2344760T3 (es) 2006-07-20 2010-09-06 Amgen Inc. Compuestos de piridona sustituidos y metodo de uso.
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
TW200829566A (en) * 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
WO2008102353A2 (en) * 2007-02-20 2008-08-28 Mobile Star Corp. Self operated computerized karaoke recording booth
AU2008303602A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010004246A (es) * 2007-10-18 2010-04-30 Novartis Ag Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas.
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20091561A1 (es) * 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
ES2392482T3 (es) * 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
SI2947072T1 (sl) 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
AU2009334869A1 (en) 2008-12-29 2011-07-14 Fovea Pharmaceuticals Substituted quinazoline compounds
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
BRPI1011247A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
SI2440547T1 (sl) * 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
KR101630283B1 (ko) * 2009-06-25 2016-06-14 한화테크윈 주식회사 영상 보안 시스템에서 부호화 장치
PH12012500382A1 (en) 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
US8553906B2 (en) * 2010-02-02 2013-10-08 Creative Technology Ltd Apparatus for enabling karaoke
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
KR20180099933A (ko) 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
CA2823753C (en) * 2011-01-05 2019-03-12 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
CA2846574C (en) * 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
CN108794411B (zh) * 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
EP2897618B1 (en) * 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CN103896922B (zh) * 2012-12-25 2017-05-03 上海科胜药物研发有限公司 新的舒尼替尼盐及其制备方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. METHOD OF TREATMENT OF CANCER
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2020061470A1 (en) * 2018-09-21 2020-03-26 Spectrum Pharmaceuticals, Inc. Novel quinazoline egfr inhibitors
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US12528796B2 (en) * 2019-04-15 2026-01-20 Tosk, Inc. Modulators of RAS GTPase
CN111072500B (zh) * 2019-11-15 2022-12-06 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
US12180220B2 (en) * 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2739505A (en) * 1952-02-04 1956-03-27 Gillette Edwin Method and means for producing composite talking pictures
GB900779A (en) * 1959-04-22 1962-07-11 Monsanto Chemicals Quinazolines
US3177218A (en) 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
US4149190A (en) * 1977-10-17 1979-04-10 Xerox Corporation Automatic gain control for video amplifier
US4408221A (en) * 1981-09-22 1983-10-04 Mccoy Reginald F H Television chroma-key systems
DK190983A (da) 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
US5051817A (en) * 1988-11-18 1991-09-24 Rohm Co., Ltd. Superimposing system
JP3206619B2 (ja) * 1993-04-23 2001-09-10 ヤマハ株式会社 カラオケ装置
JP3542821B2 (ja) * 1994-03-31 2004-07-14 ヤマハ株式会社 映像合成システムに特徴を有するカラオケ装置
US5541666A (en) * 1994-07-06 1996-07-30 General Instrument Method and apparatus for overlaying digitally generated graphics over an analog video signal
JP3662969B2 (ja) * 1995-03-06 2005-06-22 富士通株式会社 カラオケシステム
CN1110969C (zh) * 1995-04-21 2003-06-04 索尼公司 图像信号的相位同步方法、电路及合成装置
US6400374B2 (en) * 1996-09-18 2002-06-04 Eyematic Interfaces, Inc. Video superposition system and method
JP2957977B2 (ja) * 1997-10-30 1999-10-06 三洋電機株式会社 ビデオカメラ
US6514083B1 (en) * 1998-01-07 2003-02-04 Electric Planet, Inc. Method and apparatus for providing interactive karaoke entertainment
EP1072263A4 (en) * 1998-03-26 2004-03-31 Japan Tobacco Inc AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020072047A1 (en) * 1999-12-13 2002-06-13 Michelson Daniel R. System and method for generating composite video images for karaoke applications
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
US6978051B2 (en) * 2000-03-06 2005-12-20 Sony Corporation System and method for capturing adjacent images by utilizing a panorama mode
KR20020026374A (ko) * 2000-06-20 2002-04-09 요트.게.아. 롤페즈 가라오케 시스템
EP1337513A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7035915B1 (en) * 2001-09-05 2006-04-25 Cisco Technology, Inc. Method and apparatus for IP address assignment
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004092144A2 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds useful as p38 kinase inhibitors
US20070047834A1 (en) * 2005-08-31 2007-03-01 International Business Machines Corporation Method and apparatus for visual background subtraction with one or more preprocessing modules
US7570881B2 (en) * 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use

Also Published As

Publication number Publication date
US7691866B2 (en) 2010-04-06
EP1680122A1 (en) 2006-07-19
CN1882345A (zh) 2006-12-20
MXPA06003607A (es) 2006-06-05
US20050084835A1 (en) 2005-04-21
CA2542329A1 (en) 2005-04-28
US20090317359A1 (en) 2009-12-24
WO2005037285A1 (en) 2005-04-28
JP2007509059A (ja) 2007-04-12
US20050085482A1 (en) 2005-04-21
IL174470A0 (en) 2006-08-01
KR20070029110A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
AU2004281154A1 (en) 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
US7423150B2 (en) Substituted benzazoles and methods of their use as inhibitors of Raf kinase
CN100515419C (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
US8299108B2 (en) Substituted benzazoles and methods of their use as inhibitors of raf kinase
HK1067945B (en) Substituted benzazoles and use thereof as raf kinase inhibitors
HK1078779B (en) Substituted benzazoles and use thereof as raf kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application